<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37058406</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Variant enterovirus A71 found in immune-suppressed patient binds to heparan sulfate and exhibits neurotropism in B-cell-depleted mice.</ArticleTitle><Pagination><StartPage>112389</StartPage><MedlinePgn>112389</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2023.112389</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(23)00400-X</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV-A71) causes hand, foot, and mouth disease outbreaks with neurological complications and deaths. We previously isolated an EV-A71 variant in the stool, cerebrospinal fluid, and blood of an immunocompromised patient who had a leucine-to-arginine substitution on the VP1 capsid protein, resulting in increased heparin sulfate binding. We show here that this mutation increases the virus's pathogenicity in orally infected mice with depleted B cells, which mimics the patient's immune status, and increases susceptibility to neutralizing antibodies. However, a double mutant with even greater heparin sulfate affinity is not pathogenic, suggesting that increased heparin sulfate affinity may trap virions in peripheral tissues and reduce neurovirulence. This research sheds light on the increased pathogenicity of variant with heparin sulfate (HS)-binding ability in individuals with decreased B cell immunity.</AbstractText><CopyrightInformation>Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Kuo-Feng</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tee</LastName><ForeName>Han Kang</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Medicine, University of Geneva Medical School, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseligka</LastName><ForeName>Eirini D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Medicine, University of Geneva Medical School, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cagno</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Medicine, University of Geneva Medical School, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathez</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Medicine, University of Geneva Medical School, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosset</LastName><ForeName>Stéphane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Medicine, University of Geneva Medical School, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagamine</LastName><ForeName>Claude M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Comparative Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarnow</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkegaard</LastName><ForeName>Karla</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapparel</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Molecular Medicine, University of Geneva Medical School, Geneva, Switzerland. Electronic address: caroline.tapparel@unige.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI134912</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>9050-30-0</RegistryNumber><NameOfSubstance UI="D006497">Heparitin Sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006497" MajorTopicYN="N">Heparitin Sulfate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B cell</Keyword><Keyword MajorTopicYN="N">CP: Immunology</Keyword><Keyword MajorTopicYN="N">CP: Microbiology</Keyword><Keyword MajorTopicYN="N">EV-A71</Keyword><Keyword MajorTopicYN="N">EV71</Keyword><Keyword MajorTopicYN="N">VP1</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">heparan sulfate</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword><Keyword MajorTopicYN="N">oral infection</Keyword><Keyword MajorTopicYN="N">pathogenicity</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>12</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37058406</ArticleId><ArticleId IdType="mid">NIHMS1895600</ArticleId><ArticleId IdType="pmc">PMC10590055</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2023.112389</ArticleId><ArticleId IdType="pii">S2211-1247(23)00400-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hu X, Zhang Y, Zhou X, Xu B, Yang M, Wang M, Zhang C, Li J,Bai R, Xu W, and Ma X.(2012). Simultaneously typing nine serotypes of enteroviruses associated with hand, foot, and mouth disease by a GeXP analyzer-based multiplex reverse transcription-PCR assay. J. Clin. Microbiol 50, 288–293. 10.1128/JCM.05828-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.05828-11</ArticleId><ArticleId IdType="pmc">PMC3264198</ArticleId><ArticleId IdType="pubmed">22116146</ArticleId></ArticleIdList></Reference><Reference><Citation>Benckert J, and Berg T.(2011). [Diagnosis and clinical features of infection with hepatitis A and hepatitis E viruses. Transmission through drinking water and foodstuffs]. Pharm. Unserer Zeit 40, 25–29. 10.1002/pauz.201100396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pauz.201100396</ArticleId><ArticleId IdType="pubmed">21194078</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, andOoi MH (2010). Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis 10, 778–790. 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Karrasch M, Fischer E, Scholten M, Sauerbrei A, Henke A, Renz DM, Mentzel HJ, Bö er K, Böttcher S, Diedrich S, et al. (2016). A severe pediatric infection with a novel enterovirus A71 strain, Thuringia, Germany. J. Clin. Virol 84, 90–95. 10.1016/j.jcv.2016.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2016.09.007</ArticleId><ArticleId IdType="pubmed">27771495</ArticleId></ArticleIdList></Reference><Reference><Citation>Antona D, Kossorotoff M, Schuffenecker I, Mirand A, Leruez-Ville M,Bassi C, Aubart M, Moulin F, Levy-Bruhl D, Henquell C, et al. (2016). Severe paediatric conditions linked with EV-A71 and EV-D68, France, May to October 2016. Euro Surveill. 21. 10.2807/1560-7917.ES.201621.46.30402.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.201621.46.30402</ArticleId><ArticleId IdType="pmc">PMC5144948</ArticleId><ArticleId IdType="pubmed">27918268</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, Song YF, Wang L, Zhang XF, Hu YS, Hu YM, Xia JL, Li J, and Zhu FC (2016). Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev. Vaccines 15, 129–137. 10.1586/14760584.2016.1096782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1096782</ArticleId><ArticleId IdType="pubmed">26460695</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, and Koike S.(2009). Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat. Med 15, 798–801. 10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, and Shimizu H.(2009). Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat. Med 15, 794–797. 10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Chuang H, and Yang KD (2009). Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol. J 6, 141. 10.1186/1743-422X-6-141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-6-141</ArticleId><ArticleId IdType="pmc">PMC2751754</ArticleId><ArticleId IdType="pubmed">19751532</ArticleId></ArticleIdList></Reference><Reference><Citation>Su PY, Wang YF, Huang SW, Lo YC, Wang YH, Wu SR, Shieh DB, Chen SH, Wang JR, Lai MD, and Chang CF (2015). Cell surface nucleolin facilitates enterovirus 71 binding and infection. J. Virol 89, 4527–4538. 10.1128/JVI.03498-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03498-14</ArticleId><ArticleId IdType="pmc">PMC4442404</ArticleId><ArticleId IdType="pubmed">25673703</ArticleId></ArticleIdList></Reference><Reference><Citation>Du N, Cong H, Tian H, Zhang H, Zhang W, Song L, and Tien P.(2014). Cell surface vimentin is an attachment receptor for enterovirus 71. J. Virol 88, 5816–5833. 10.1128/JVI.03826-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03826-13</ArticleId><ArticleId IdType="pmc">PMC4019121</ArticleId><ArticleId IdType="pubmed">24623428</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SL, Chou YT, Wu CN, and Ho MS (2011). Annexin II binds tocapsid protein VP1 of enterovirus 71 and enhances viral infectivity. J. Virol 85, 11809–11820. 10.1128/JVI.00297-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00297-11</ArticleId><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing J, Wang Y, Sun Y, Huang J, Yan W, Wang J, Su D, Ni C, Li J, Rao Z, et al. (2014). Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog. 10, e1004422. 10.1371/journal.ppat.1004422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004422</ArticleId><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="pubmed">25275585</ArticleId></ArticleIdList></Reference><Reference><Citation>He QQ, Ren S, Xia ZC, Cheng ZK, Peng NF, and Zhu Y.(2018). Fibronectin facilitates enterovirus 71 infection by mediating viral entry. J. Virol 92, e02251–17. 10.1128/JVI.02251-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02251-17</ArticleId><ArticleId IdType="pmc">PMC5899198</ArticleId><ArticleId IdType="pubmed">29467312</ArticleId></ArticleIdList></Reference><Reference><Citation>Too IHK, Bonne I, Tan EL, Chu JJH, and Alonso S.(2018). Prohibitin plays a critical role in Enterovirus 71 neuropathogenesis. PLoS Pathog. 14, e1006778. 10.1371/journal.ppat.1006778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006778</ArticleId><ArticleId IdType="pmc">PMC5764453</ArticleId><ArticleId IdType="pubmed">29324904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Poh CL, Sam IC, and Chan YF (2013). Enterovirus 71 usescell surface heparan sulfate glycosaminoglycan as an attachment receptor. J. Virol 87, 611–620. 10.1128/JVI.02226-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02226-12</ArticleId><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordey S, Petty TJ, Schibler M, Martinez Y, Gerlach D, van Belle S, Turin L, Zdobnov E, Kaiser L, and Tapparel C.(2012). Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog. 8, e1002826. 10.1371/journal.ppat.1002826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002826</ArticleId><ArticleId IdType="pmc">PMC3406088</ArticleId><ArticleId IdType="pubmed">22910880</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseligka ED, Sobo K, Stoppini L, Cagno V, Abdul F, Piuz I, Meylan P, Huang S, Constant S, and Tapparel C.(2018). A VP1 mutation acquired during an enterovirus 71 disseminated infection confers heparan sulfate binding ability and modulates ex vivo tropism. PLoS Pathog. 14, e1007190. 10.1371/journal.ppat.1007190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007190</ArticleId><ArticleId IdType="pmc">PMC6093697</ArticleId><ArticleId IdType="pubmed">30075025</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JY, Weng KF, Chang CK, Gong YN, Huang GJ, Lee HL,Chen YC, Huang CC, Lu JY, Huang PN, et al. (2021). Enterovirus A71 induces neurological diseases and dynamic variants in oral infection of human SCARB2-transgenic weaned mice. J. Virol 95, e0089721. 10.1128/JVI.00897-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00897-21</ArticleId><ArticleId IdType="pmc">PMC8513470</ArticleId><ArticleId IdType="pubmed">34379497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Sudaka Y, Takashino A, Imura A, Fujii K, and Koike S(2018). Amino acid variation at VP1–145 of enterovirus 71 determines attachment receptor usage and neurovirulence in human scavenger receptor B2 transgenic mice. J. Virol 92, e00681–18. 10.1128/JVI.00681-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00681-18</ArticleId><ArticleId IdType="pmc">PMC6052303</ArticleId><ArticleId IdType="pubmed">29848584</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Sudaka Y, Takashino A, Kobayashi K, Kataoka C, Suzuki T, Iwata-Yoshikawa N, Kotani O, Ami Y, Shimizu H, et al. (2018). VP1 amino acid residue 145 of enterovirus 71 is a key residue for its receptor attachment and resistance to neutralizing antibody during cynomolgus monkey infection. J. Virol 92, e00682–18. 10.1128/JVI.00682-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00682-18</ArticleId><ArticleId IdType="pmc">PMC6052295</ArticleId><ArticleId IdType="pubmed">29848582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke X, Zhang Y, Liu Y, Miao Y, Zheng C, Luo D, Sun J, Hu Q, Xu Y, Wang H, and Zheng Z.(2020). A single mutation in the VP1 gene of enterovirus 71 enhances viral binding to heparan sulfate and impairs viral pathogenicity in mice. Viruses 12. 10.3390/v12080883.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12080883</ArticleId><ArticleId IdType="pmc">PMC7472116</ArticleId><ArticleId IdType="pubmed">32823486</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee HK, Tan CW, Yogarajah T, Lee MHP, Chai HJ, Hanapi NA, Yusof SR, Ong KC, Lee VS, Sam IC, and Chan YF (2019). Electrostatic interactions at the five-fold axis alter heparin-binding phenotype and drive enterovirus A71 virulence in mice. PLoS Pathog. 15, e1007863. 10.1371/journal.ppat.1007863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007863</ArticleId><ArticleId IdType="pmc">PMC6881073</ArticleId><ArticleId IdType="pubmed">31730673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Mizuta K, and Koike S.(2020). Heparan sulfate attachment receptor is a major selection factor for attenuated enterovirus 71 mutants during cell culture adaptation. PLoS Pathog. 16, e1008428. 10.1371/journal.ppat.1008428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008428</ArticleId><ArticleId IdType="pmc">PMC7105141</ArticleId><ArticleId IdType="pubmed">32187235</ArticleId></ArticleIdList></Reference><Reference><Citation>Quartier P, Tournilhac O, Archimbaud C, Lazaro L, Chaleteix C, Millet P, Peigue-Lafeuille H, Blanche S, Fischer A, Casanova JL, et al. (2003). Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin. Infect. Dis 36, e47–e49. 10.1086/345746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/345746</ArticleId><ArticleId IdType="pubmed">12539090</ArticleId></ArticleIdList></Reference><Reference><Citation>Grisariu S, Vaxman I, Gatt M, Elias S, Avni B, Arad A, Pasvolsky O,Raanani P, and Paltiel O.(2017). Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature. Hematol. Oncol 35, 591–598. 10.1002/hon.2365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2365</ArticleId><ArticleId IdType="pubmed">27734521</ArticleId></ArticleIdList></Reference><Reference><Citation>Servais S, Caers J, Warling O, Frusch N, Baron F, De Prijck B, and Beguin Y.(2010). Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma. Br. J. Haematol 150, 379–381. 10.1111/j.1365-2141.2010.08202.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2010.08202.x</ArticleId><ArticleId IdType="pubmed">20408837</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil T, Hannah R, Hui CH, and Qiao M.(2022). Disseminated enterovirus infection in a patient treated with obinutuzumab. J. Med. Virol 94, 439–441. 10.1002/jmv.27370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27370</ArticleId><ArticleId IdType="pubmed">34590740</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, Su IJ, Wang JR, Yeh TM, Chen SH, and Yu CK (2004). A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J. Virol 78, 7916–7924. 10.1128/JVI.78.15.7916-7924.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.7916-7924.2004</ArticleId><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Sam IC, Lee VS, Wong HV, and Chan YF (2017). VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology 501, 79–87. 10.1016/j.virol.2016.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.11.009</ArticleId><ArticleId IdType="pubmed">27875780</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, and Ferrin TE (2004). UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem 25, 1605–1612. 10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Earley DF, Bailly B, Maggioni A, Kundur AR, Thomson RJ, Chang CW, and von Itzstein M.(2019). Efficient blocking of enterovirus 71 infection by heparan sulfate analogues acting as decoy receptors. ACS Infect. Dis 5, 1708–1717. 10.1021/acsinfecdis.9b00070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.9b00070</ArticleId><ArticleId IdType="pubmed">31307190</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Nagata N, Sato Y, Ong KC, Wong KT, Yamayoshi S, Shimanuki M, Shitara H, Taya C, and Koike S.(2013). Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc. Natl. Acad. Sci. USA 110, 14753–14758. 10.1073/pnas.1217563110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1217563110</ArticleId><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Misumi I, and Whitmire JK (2014). B cell depletion curtails CD4+ T cell memory and reduces protection against disseminating virus infection. J. Immunol 192, 1597–1608. 10.4049/jimmunol.1302661.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302661</ArticleId><ArticleId IdType="pmc">PMC3925510</ArticleId><ArticleId IdType="pubmed">24453250</ArticleId></ArticleIdList></Reference><Reference><Citation>Seikrit C, and Pabst O.(2021). The immune landscape of IgA induction in the gut. Semin. Immunopathol 43, 627–637. 10.1007/s00281-021-00879-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-021-00879-4</ArticleId><ArticleId IdType="pmc">PMC8551147</ArticleId><ArticleId IdType="pubmed">34379174</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamoto S, Tran TH, Maruya M, Suzuki K, Doi Y, Tsutsui Y, Kato LM, and Fagarasan S.(2012). The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science 336, 485–489. 10.1126/science.1217718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1217718</ArticleId><ArticleId IdType="pubmed">22539724</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith FL, and Baumgarth N.(2019). B-1 cell responses to infections. Curr. Opin. Immunol 57, 23–31. 10.1016/j.coi.2018.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2018.12.001</ArticleId><ArticleId IdType="pmc">PMC6521837</ArticleId><ArticleId IdType="pubmed">30685692</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam JH, and Baumgarth N.(2019). The multifaceted B cell response toinfluenza virus. J. Immunol 202, 351–359. 10.4049/jimmunol.1801208.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1801208</ArticleId><ArticleId IdType="pmc">PMC6327962</ArticleId><ArticleId IdType="pubmed">30617116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuss SK, Etheredge CA, and Pfeiffer JK (2008). Multiple host barriers restrict poliovirus trafficking in mice. PLoS Pathog. 4, e1000082. 10.1371/journal.ppat.1000082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000082</ArticleId><ArticleId IdType="pmc">PMC2390757</ArticleId><ArticleId IdType="pubmed">18535656</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgescu MM, Balanant J, Ozden S, and Crainic R.(1997). Random selection: a model for poliovirus infection of the central nervous system. J. Gen. Virol 78, 1819–1828. 10.1099/0022-1317-788-1819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-788-1819</ArticleId><ArticleId IdType="pubmed">9266975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SC, Li WC, Chen GW, Tsao KC, Huang CG, Huang YC, Chiu CH, Kuo CY, Tsai KN, Shih SR, and Lin TY (2012). Genetic characterization of enterovirus 71 isolated from patients with severe disease by comparative analysis of complete genomes. J. Med. Virol 84, 931–939. 10.1002/jmv.23287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23287</ArticleId><ArticleId IdType="pubmed">22499017</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Zou Q, Chen L, Zhang H, and Wang Y.(2011). Molecular analysis of virulent determinants of enterovirus 71. PLoS One 6, e26237. 10.1371/journal.pone.0026237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026237</ArticleId><ArticleId IdType="pmc">PMC3198388</ArticleId><ArticleId IdType="pubmed">22039449</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Fu C, Wu S, Chen X, Shi Y, Zhou B, Zhang L, Zhang F, Wang Z, Zhang Y, et al. (2014). A novel finding for enterovirus virulence from the capsid protein VP1 of EV71 circulating in mainland China. Virus Gene. 48, 260–272. 10.1007/s11262-014-1035-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-014-1035-2</ArticleId><ArticleId IdType="pubmed">24442718</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Wu X, Huang K, Li L, Zheng L, Wan C, He ML, and Zhao W.(2014). The variations of VP1 protein might be associated with nervous system symptoms caused by enterovirus 71 infection. BMC Infect. Dis 14, 243. 10.1186/1471-2334-14-243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-14-243</ArticleId><ArticleId IdType="pmc">PMC4101859</ArticleId><ArticleId IdType="pubmed">24886383</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Badmanathan M, Devi S, Leong KL, Cardosa MJ, and Wong KT (2008). Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J. Neuropathol. Exp. Neurol 67, 532–542. 10.1097/NEN.0b013e31817713e7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31817713e7</ArticleId><ArticleId IdType="pubmed">18520772</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CS, Yao YC, Lin SC, Lee YP, Wang YF, Wang JR, Liu CC, Lei HY, and Yu CK (2007). Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J. Virol 81, 8996–9003. 10.1128/JVI.00236-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00236-07</ArticleId><ArticleId IdType="pmc">PMC1951457</ArticleId><ArticleId IdType="pubmed">17567704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobardt MD, Salmon P, Wang L, Esko JD, Gabuzda D, Fiala M, Trono D, Van der Schueren B, David G, and Gallay PA (2004). Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J. Virol 78, 6567–6584. 10.1128/JVI.78.12.65676584.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.12.65676584.2004</ArticleId><ArticleId IdType="pmc">PMC416544</ArticleId><ArticleId IdType="pubmed">15163749</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Ami Y, Wakita T, and Shimizu H.(2008). Cooperative effect ofthe attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J. Virol 82, 1787–1797. 10.1128/JVI.01798-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01798-07</ArticleId><ArticleId IdType="pmc">PMC2258712</ArticleId><ArticleId IdType="pubmed">18057246</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua BH, Phuektes P, Sanders SA, Nicholls PK, and McMinn PC(2008). The molecular basis of mouse adaptation by human enterovirus 71. J. Gen. Virol 89, 1622–1632. 10.1099/vir.0.83676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.83676-0</ArticleId><ArticleId IdType="pubmed">18559932</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Wang YF, Yu CK, Su IJ, and Wang JR (2012). Mutations in VP2 and VP1 capsid proteins increase infectivity and mouse lethality of enterovirus 71 by virus binding and RNA accumulation enhancement. Virology 422, 132–143. 10.1016/j.virol.2011.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.10.015</ArticleId><ArticleId IdType="pubmed">22078110</ArticleId></ArticleIdList></Reference><Reference><Citation>Victorio CBL, Xu Y, Ng Q, Meng T, Chow VT, and Chua KB(2016). Cooperative effect of the VP1 amino acids 98E, 145A and 169F in the productive infection of mouse cell lines by enterovirus 71 (BS strain). Emerg. Microbes Infect 5, e60. 10.1038/emi.2016.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.56</ArticleId><ArticleId IdType="pmc">PMC4932649</ArticleId><ArticleId IdType="pubmed">27329847</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y, Lee H, Hafenstein S, Kataoka C, Wakita T, Bergelson JM, and Shimizu H.(2013). Enterovirus 71 binding to PSGL-1 on leukocytes: VP1–145 acts as a molecular switch to control receptor interaction. PLoS Pathog. 9, e1003511. 10.1371/journal.ppat.1003511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003511</ArticleId><ArticleId IdType="pmc">PMC3723564</ArticleId><ArticleId IdType="pubmed">23935488</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L, and Muench H.(1938). A simple method of estimating fifty percent endpointsAm. Am. J. Epidemiol 27, 493–497.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>